Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. ESMO
  2. Guidelines
  3. Guidelines by topic

ESMO Clinical Practice Guidelines: Endocrine and Neuroendocrine Cancers

Latest enhanced and revised set of guidelines

ESMO has Clinical Practice Guidelines on the following endocrine and neuroendocrine cancers: adrenocortical carcinomas and malignant phaeochromocytomas, Merkel-cell carcinoma, gastroenteropancreatic neuroendocrine neoplasms, lung and thymic carcinoids, rare endocrine tumours, and thyroid cancer. They include information on incidence, diagnosis, staging and risk assessment, treatment, response evaluation and follow-up.

The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best standards of cancer care, based on the findings of evidence-based medicine.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.